Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China.
Protein J. 2012 Apr;31(4):328-36. doi: 10.1007/s10930-012-9407-8.
To obtain a bifunctional protein simultaneously showing bioactivity of anticoagulant and fibrinolytic for use in the treatment of thrombotic diseases, we constructed a fusion protein (HV12p-rPA) containing C-terminal 12-residue of hirudin-PA (HV12p) and reteplase (rPA). The fusion protein, in which HV12p was linked to rPA via Gly-Gly-Gly, was successfully expressed in an inactive form of inclusion bodies in Escherichia coli. HV12p-rPA was identified by sodium dodecylsulfate-polyacrylamide gel electrophoresis. The expression level of HV12p-rPA was optimized by an orthogonal method and finally enhanced from 12 % to approximate 30 %. We also deeply investigated the condition of renaturation of HV12p-rPA, and the inactive protein was partly renatured through various conditions. The refolding efficacy of HV12p-rPA estimated by the recovery of fibrinolytic activity varied from 0.03 % to 16.6 % and the anticoagulant activity fluctuated in the range from 41 to 2,297 ATU/mg. Bioassays indicated that the resulted fusion protein, as expected, exhibited both fibrinolytic and anticoagulant activities. These works laid a foundation for further characterization of HV12p-rPA.
为了获得一种同时具有抗凝和纤溶活性的双功能蛋白,用于治疗血栓性疾病,我们构建了一种融合蛋白(HV12p-rPA),它包含了水蛭素-PA(HV12p)和瑞替普酶(rPA)的 C 端 12 个残基。融合蛋白通过甘氨酸-甘氨酸-甘氨酸连接到 rPA 上,在大肠杆菌中以无活性的包涵体形式成功表达。通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳鉴定了 HV12p-rPA。通过正交方法优化了 HV12p-rPA 的表达水平,最终从 12%提高到接近 30%。我们还深入研究了 HV12p-rPA 的复性条件,通过各种条件使无活性蛋白部分复性。通过纤溶活性恢复估计的 HV12p-rPA 的重折叠效率在 0.03%至 16.6%之间变化,抗凝活性在 41 至 2297 ATU/mg 之间波动。生物测定表明,所得到的融合蛋白如预期的那样,同时具有纤溶和抗凝活性。这些工作为进一步表征 HV12p-rPA 奠定了基础。